Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:36:05 EDT Mon 30 Jun 2025
Enter Symbol
or Name
USA
CA



Q:RSLS - RESHAPE LIFESCIENCES INC - https://www.reshapelifesciences.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RSLS - Q5.52.40·2.452.52.44136.02917142.38  2.46  2.38414.9893  2.2317:45:43Jun 2715 min RT 2¢

Recent Trades - Last 10 of 714
Time ETExPriceChangeVolume
17:45:43Q2.40-0.0429
17:14:31Q2.44 20
17:02:08Q2.450.016
17:01:16Q2.450.01200
16:55:31Q2.450.015
16:49:19Q2.44 2
16:47:04Q2.44 2
16:41:47Q2.44 1
16:40:09Q2.4017-0.03831
16:29:04Q2.41-0.031,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-27 09:01U:RSLSNews ReleaseReShape Lifesciences(TM) Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
2025-06-26 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
2025-06-25 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
2025-06-12 08:25U:RSLSNews ReleaseReShape Lifesciences(TM) Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
2025-06-09 09:00U:RSLSNews ReleaseReShape Lifesciences(TM) Announces Pricing of $2.6 Million Public Offering
2025-06-03 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
2025-05-21 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
2025-05-07 08:31U:RSLSNews ReleaseReShape Lifesciences Announces 1-for-25 Reverse Stock Split
2025-05-02 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
2025-04-28 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
2025-04-21 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
2025-04-09 16:05U:RSLSNews ReleaseReShape Lifesciences(TM) Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
2025-04-07 16:05U:RSLSNews ReleaseReShape Lifesciences(TM) Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
2025-03-10 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
2025-02-25 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band(TM) 2.0 FLEX
2025-02-15 23:18U:RSLSNews ReleaseReShape Lifesciences(TM) Announces Pricing of Upsized $6.0 Million Public Offering
2025-02-03 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
2025-01-13 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
2024-11-14 16:05U:RSLSNews ReleaseReShape Lifesciences(TM) Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
2024-11-12 16:05U:RSLSNews ReleaseReShape Lifesciences(TM) to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update